Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
Adial Pharmaceuticals expands its patent estate to cover a unique genetic diagnostic approach for treating alcohol and drug dependencies. The Company's lead drug, AD04, shows promising results in specific genotype patients, potentially revolutionizing addiction treatment.
The expansion of Adial Pharmaceuticals' patent estate is a strategic move that strengthens the company's competitive position in the addiction treatment market. The patent for the combination of genetic diagnostics and AD04, their lead investigational drug, represents a significant advancement in personalized medicine for alcohol use disorder (AUD) and opioid use disorder (OUD). The ability to identify specific genotypes that respond well to treatment could lead to more effective and targeted therapies, potentially improving patient outcomes.
From a medical research perspective, the implications of such a tailored approach are profound. It suggests a shift from a one-size-fits-all treatment model to one that is more nuanced, taking into account individual genetic differences. This could reduce the trial-and-error aspect of prescribing medications, thereby enhancing the efficiency of healthcare resources and possibly reducing the economic burden of addiction on society.
With the CEO's statement on the addressable market for AD04 being approximately $40 billion in the U.S. alone, the financial potential for Adial Pharmaceuticals is substantial. The market for addiction treatment is vast and underserved and a successful genetically targeted therapy could capture a significant share. However, it's important to consider the challenges of market penetration, including regulatory hurdles, acceptance by the medical community and competition from existing and future treatments.
Investors should note the long-term potential of such a personalized treatment approach, which could lead to a paradigm shift in addiction therapy. If Adial can navigate the clinical and regulatory pathways successfully, the expanded patent estate could serve as a barrier to entry for competitors, potentially leading to a strong market position and a favorable impact on the company's valuation.
The announcement of the patent award is likely to be viewed positively by investors, as it enhances the company's intellectual property portfolio and may contribute to long-term value creation. The focus on genetically targeted treatment is an innovative approach in the addiction space and the post hoc analysis of Phase 3 results indicates a promising efficacy profile for AD04 in patients with specific genotypes.
Financially, the development of AD04 and the expansion of the patent estate could lead to significant R&D expenses in the near-term. However, the potential market size and the ability to target treatment effectively may justify the investment. The company's stock price could see an uptick as investors anticipate the progress of AD04 through the clinical and regulatory pipeline, but it is essential to balance this optimism with the inherent risks of drug development, including potential delays or unfavorable clinical trial outcomes.
02/13/2024 - 09:15 AM
Expands patent estate covering Adial’s unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence
CHARLOTTESVILLE, Va., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced it has been awarded an important patent which expands the estate covering the combination of the Company’s proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) and drug dependencies, such as opioid use disorder (OUD), with the Company’s lead investigational new drug product AD04.
“Following a post hoc analysis of our ONWARD™ Phase 3 results, we identified patients with specific genotypes that responded extremely well to AD04. Given the positive results, we believe the combination of our genetic diagnostic and AD04 can provide a tailored treatment solution for those who suffer from AUD and OUD,” commented Cary Claiborne, CEO of Adial Pharmaceuticals. “This key patent significantly expands the scope of our intellectual property (IP) protection in the United States to cover important aspects of our unique molecular approach to diagnosing and potentially treating AUD and other drug dependencies such as OUD. By combining a tool to predict which patients are most likely to benefit from AD04 treatment, with AD04’s clinical track record of reducing heavy drinking days among patients with specific genotypes, we believe we can transform the lives of millions affected by AUD and other dependencies. Among patients with the target genotypes, we believe the addressable market for AD04 is approximately $40 billion , in the U.S. alone. We remain committed to further understanding the genetic factors that affect addiction and bringing a personalized approach to addiction with AD04.”
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of AUD in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company’s proprietary companion diagnostic genetic test. ONWARD showed promising results in reducing heavy drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com
Forward Looking Statements
This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the combination of the Company’s genetic diagnostic and AD04 providing a tailored treatment solution for those who suffer from AUD and OUD, transforming the lives of millions affected by AUD and other dependencies by the Company combining a tool to predict which patients are most likely to benefit from AD04 treatment with AD04’s clinical track record of reducing heavy drinking days among patients with specific genotypes, the addressable market for AD04 being approximately $40 billion among patients with the target genotypes in the U.S. alone, bringing a personalized approach to addiction with AD04 and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2022, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Contact: ADIL@crescendo-ir.com
What did Adial Pharmaceuticals announce regarding its patent estate?
Adial Pharmaceuticals announced the expansion of its patent estate to cover a genetic diagnostic approach for treating alcohol and drug dependencies.
What is the significance of the new patent for Adial Pharmaceuticals?
The new patent protects the combination of the Company's genetic diagnostic and AD04 drug for targeted treatment of alcohol use disorder and drug dependencies.
What is the potential market size for AD04 according to Adial Pharmaceuticals?
Adial Pharmaceuticals estimates the addressable market for AD04 to be approximately $40 billion in the U.S. alone among patients with specific genotypes.
Who commented on the positive results of the genetic diagnostic and AD04 combination?
Cary Claiborne, the CEO of Adial Pharmaceuticals, commented on the positive results of the genetic diagnostic and AD04 combination.
